INTRODUCTION
In Western Medicine (WM), acute stroke is also known as acute cerebrovascular disease. It includes acute cerebral infarction (ACI), acute cerebral hemorrhage (ACH), cerebral embolism and subarachnoid hemorrhage. 1 Stroke can be divided into two types: ischemic stroke and hemorrhagic stroke. Ischemic stroke includes cerebral infarction and cerebral thrombosis, and the most common case of hemorrhagic stroke is cerebral apoplexy. Stroke has one of the highest incidences of the cerebrovascular diseases. It results in high rates of morbidity, mortality and disability, and often contributes to sequelae that may seriously threaten human health. The majority of survivors (60%) require the help of medical institutions; their lives may be dramatically affected and the possibility of recurrence is high. At the same time, stroke is one of the most expensive diseases to treat, which can bring a great deal of economic burden to patients. [2] [3] [4] Results of some studies have shown that the incidence of stroke is increasing. Therefore, methods to treat acute stroke effectively and reduce the impact of its sequelae have become foci for research. 5 Qingkailing injection (QKL) is derived from Angongniuhuang pills. Its main ingredients include Niuhuang (Calculus Bovis), Shuiniujiao (Cornu Bubali), Huangqin (Radix Scutellariae Baicalensis), Jinyinhua (Flos Lonicerae), and Zhizi (Fructus Gardeniae). It has a variety of functions: as an antifebrile agent and hepato-protectant, in regulating immunity, promoting the absorption of intracranial hematoma and reducing cerebral edema. 6 QKL is used widely in the clinical setting in the areas of cerebrovascular disease, acute infectious diseases, pediatric diseases and otorhinolaryngologic diseases, among others. It has achieved significant effects in the treatment of stroke, hepatitis, and in cardiovascular and pediatric diseases. 7 Recently, more and more clinical cases have been reported describing QKL as an emergency treatment for acute stroke with fever. 8 All of these reports have shown that QKL could increase the efficacy rate of emergency rescue in Traditional Chinese Medicine (TCM). Although there have been several previous Meta-analyses regarding stroke, [9] [10] [11] [12] [13] their focus has been on either cerebral infarction or cerebral hemorrhage only. Rather, this systematic review aims to evaluate objectively the efficacy and safety of QKL in treating acute stroke without classification, providing a scientific basis for its clinical use in acute stroke, the reason of no classification was QKL was efficacy in both hemorrhagic and ischemic stroke that indicated in one study.
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MATERIALS AND METHODS
Study search
Two reviewers retrieved randomized controlled trials (RCTs) by searching the following databases from January 1979 to March 2013: the China National Knowledge Infrastructure Database, Wan fang Database, China Science and Technology Journal Database, Chinese Biomedical Literature database, PubMed, and the Cochrane Library. The search terms included "Qingkailing" as a MeSH term and then "stroke or cerebrovascular diseases" for secondary retrieval. Studies published in English or Chinese were considered.
Inclusion criteria
Studies meeting the following criteria were included. Clinical RCTs used QKL to treat acute stroke, regardless of blinding. The diagnostic criterion in terms of TCM was "apoplexy diagnostic efficacy assessment standards"; that used in terms of WM was "the various types of cerebrovascular disease diagnostic points", as determined in 1995. 15 Diagnoses were validated using computer tomography or magnetic resonance imaging scanning. The courses of disease were 7 days or shorter; this is considered the acute phase of stroke. All patients were experiencing the first onset of stroke, and no limits were placed on age, gender, race or severity of disease. The control group was treated with predominantly two types of conventional WM: patients with cerebral hemorrhage received hemostatics, drugs lowering intracranial pressure, anti-hypertensives and anti-infectives; patients with cerebral infarction received vasodilators and anti-hyperlipidemics. Both types of patients required brain cell activators. The experimental group was treated with WM on the same basis as the control group, but combined with QKL. None of the therapies was combined with any other Chinese medicine, surgery or acupuncture. The dosages and treatment courses were not limited. The primary outcome was the total effective rate, using the following formula: total effective rate=(number of recovered patients + number of patients with significant progress + number of patients with progress)/total number × 100% . Efficacy criteria predominantly referred to a reduction in the neurological deficit score, and to the living ability of patients (or the degree of disability). Recovery was determined when the functional deficit score decreased by between 90% and 100% , and the degree of disability was 0. Significant progress was determined when the functional deficit score decreased by between 46% and 89%, and the degree of disability was 1. Progress was determined when the functional deficit score decreased by between 18% and 45%. No change or deterioration was determined when the functional deficit score decreased by <18%. 15 Secondary outcomes were: the degree of absorption of cerebral hematoma, the improvement of neurological deficits, restoration of awareness (based on the duration of patients' unconsciousness, and wake-up time), hemorheology index, and the number of adverse drug reactions (ADR)/adverse drug events (ADE) identified. The degree of absorption of the cerebral hematoma was judged by hematoma size and the following absorption rate calculation formula: V=1/2×L×S×the slice, where L is the longest diameter of the largest hematoma, S is the width, and the 'slice' is the layers of lesion. 16 The absorption rate of the hematoma= (before treatment -after)/treatment before × 100% . The judgment of the degree of neurological deficit was based on the standard score of the degree of neurological deficit of stroke, as determined in 1995: light 0-15 points, medium 16-30 points and heavy 31-45 points. The evaluation of clinical efficacy= (points before -after)/points before treatment × 100%.
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Data extraction and quality assessment For the included studies, two reviewers extracted the data and screened them according to the inclusion criteria. Any disagreements on data extraction and study evaluation were resolved through discussion. The extracted data included study type, patients' characteristics, and information about treatment. We assessed the risk of bias in the included trials strictly according to the Cochrane risk of bias tool. This addressed random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases. For each item, there were three grades of risk: low risk of bias, unclear, and high risk of bias. When inadequate information was presented in the article and we were unable to explicitly judge "high" or "low", the item was judged as "unclear". Two researchers independently completed and mutually checked the allocated grades. Any dispute was resolved through discussion or with the assistance of a third researcher.
Statistical analysis
The Revman 5.2 software package that produced and updated by the Nordic Cochrane Centre was used to analyze the collected data. Relative risk (RR) was used for dichotomous data, and mean difference (MD) was used for continuous variables, both with a 95% confidence interval (95% CI), P<0.05 was considered statistically significant between experimental and control group. The Chi-square test was used for checking the heterogeneity between studies, and I² was used to show the size of heterogeneity. If P>0.1 and I²< 25% , there was determined to be little heterogeneity between studies, then we used a fixed effect model, otherwise we should use a random effect model. If the number of included trials was sufficient, a funnel plot would be carried out to assess publication bias. Because we focused on stroke comprehensively in the study, the comparison was split into three sub-groups: ACI, ACH and a mixed sub-group. This took into account the differences in therapy between the different sub-groups. Sensitivity analysis was performed on "the total effective rate" indicators, to indicate the stability of the result.
RESULTS
Analysis of literature and assessment of quality
In this review, 484 articles were retrieved from the databases listed above. After excluding duplications, reviews and obviously irrelevant studies by reading the titles and abstracts, 141 papers were downloaded for further assessment. After reading the full texts, studies that did not meet the inclusion criteria, non-RCTs, studies in which there was a lack of information regarding the control group, or individual clinical cases, were excluded. A total of 13 studies were eventually included, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] all published in Chinese Journal Literature Databases from 1995 to 2011 (Figure 1 ). 
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Therefore, 1110 patients were included in the systematic review. The QKL group consisted of 585 patients, while the control group consisted of 525 patients. All of the patients were undergoing their first onset of stroke, and received treatment in hospital within a week. The average age of the patients was approximately 62.9 years, and all of the trials included more males (60% ) than females. Study quality was evaluated by the Cochrane risk of bias tool. All of the studies referred to randomization, but did not describe the method of randomization and blinding. Two studies appeared to have incomplete outcome data (Figures 2 and 3 ).
Total effective rate
All the studies compared the total effective rate between two groups. The analysis was divided into three sub-groups, according to the classification of stroke: ACH, ACI and the mixed sub-group containing both ACI and ACH. There were four studies [16] [17] [18] [19] in the ACH sub-group, five studies [20] [21] [22] [23] [24] in the ACI sub-group and four studies [25] [26] [27] [28] in the mixed sub-group. Following the tests of heterogeneity, the fixed effects model could be used for all three sub-groups, for which the result of the test of heterogeneity of the ACH sub-group was P=0. 27 (Figure 4) . Because there was heterogeneity between the three subgroups (P=0.11, I² =55.1>25%), we did not merge the results.
Sensitivity analysis
To confirm the stability of the total effective rate results, we removed the most and the least weighted of every sub-group, and changed from fixed mode to random mode. In the ACH sub-group, after removing the most weighted (Guo et There was no clear difference compared with the previous results, so the degree of sensitivity of the study was not high.
Degree of absorption of cerebral hematoma
Two studies 16, 17 mentioned hematoma size and absorption. Following the test for heterogeneity (P= 0.93>0.1, I² =0<25% ), we used a fixed model. The Meta-analysis showed that QKL combined with WM was better than WM alone in promoting the absorption of hematoma. The statistical difference between the two groups was significant [MD=-3.73, 95%CI (-4.48, -2.98), P<0.000 01] ( Figure 5 ). 21 Lang SH 2000 23 Liu Q 2004 26 Li YQ 2005 19 Lv J 1998 24 Shou XY 1995 28 Wang AJ 2006 25 Wang QF 2011 17 Wang Y 2000A 27 Zeng H 2003 20 Zhang S 2011 16 Zhang YY 2003 22 Wu JR et al. / Systematic Review 
Improvement of neurological deficit
Three studies 16, 20, 21 mentioned the improvement of neurological deficit scores. One study 16 was in the ACH sub-group, the compared result was MD=-4.08 [95% CI ( -8.00, -0.16), P=0.04]. There was little difference between the two groups. The test for heterogeneity of the ACI sub-group (P= 0.19>0.1, I² = 41>25% ) indicated that a random model should be used. The Meta-analysis showed that combined with WM, QKL was more effective in improving neurological deficit. There was a statistically significant difference between the two groups [MD=-5.60, 95% CI (-8.50, -2.70), P=0.0002] (Figure 6 ).
Improvement of awareness
Only one study 27 that in the sub-group of mixed mentioned improvement of awareness. The Meta-analysis showed that QKL could improve the disturbance of consciousness, and the statistical difference between the experimental and control group was significant [RR=1.56, 95% CI (1.09, 2.21), P= 0.01].
Whole blood viscosity coefficient
Hyperviscosity can lead to slower blood flow, which makes it easy for blood to form thrombose and cause subsequent stroke. Two studies 24, 25 referred to the blood viscosity coefficient, the results showing that QKL could reduce the whole blood viscosity coefficient. 
Safety
Only 5 studies 19, [23] [24] [25] [26] mentioned clearly that there were no ADRs reported in the included studies. While the other 8 studies did not pay sufficient attention to the safety aspects of QKL use, accordingly, we could not conclude that QKL was absolutely safe.
DISCUSSION
Following the literature analysis, we concluded that based on WM, QKL was effective when used for any pattern of acute stroke. It could improve the total effective rate, promote the absorption of brain hematoma, decrease the degree of neurological deficit, and reduce awareness restoration time and blood viscosity. This could be expected to not only save patients' lives, but also reduce the degree of sequelae and recurrence of acute stroke. The result of this Meta-analysis was supported by the findings of previous research. [9] [10] [11] [12] [13] In TCM, the basic pathogenesis of stroke is stagnation of blood. In the acute phase of the disease, patients may have inherent deficiency syndrome, while externally, a positive syndrome may be present. 29 During the acute phase of stroke in particular, the positive syndrome is the main cause of pathogenesis such as liver wind, heat evil, phlegm and blood stasis, excess syndromes of the Fu-organs and aural obstruction. Therefore, the treatment of stroke should start with heat-clearing detoxification, blood stasisactivating collaterals and awareness recovery. From the perspective of pathology, ACH and ACI may result in partial disorder of blood circulation, the formation of cerebral edema, 30 breaking the blood-brain barrier and increasing free radicals. An animal experiment 31 has shown that the degree of brain damage was significantly positively correlated with the increase of free radicals. The prognosis of stroke has a very close relationship with the effect of treatment in the acute phase. 29 Combining the opinions of TCM and Western Medicine, the choice of medicine in the acute phase is very important. QKL is derived from Angongniuhuang pills. Its main actions are heatclearing and detoxifying, eliminating phlegm and freeing channels, tranquilizing and allaying agitation, recovering consciousness, and keeping the balance of Qi and blood. QKL can also scavenge free radicals effectively, which can reduce the occurrence of sequelae. 31 Recent research has indicated that QKL can also correct metabolic disorders, improve cerebral circulation and cerebral edema, and enhance brain cells' tolerance to hypoxia. This can protect the brain cells, reduce infarct size, and promote the absorption of hematoma. 30 Based on the efficacy and pharmacological effects described above, QKL may be the first choice for the clinical treatment of acute stroke. Combining this with the results of the Meta-analysis, we can conclude that QKL combined with WM has a relatively good effect, regardless of stroke disease-type. Though there was no ADRs reported in the Meta-analysis, the number of ADR reports regarding QKL has gradually increased in clinical practice. 32 From this, we may assume that the clinical use of QKL for stroke may be relatively safe. Analyzing the ADR reports from the clinical setting, the results show that excessive dose is one of the reasons for QKL-related anaphylactic shock. In addition, the occurrence of ADRs may also be associated with the combining of drugs. Therefore, medical staff should pay special attention to controlling the dose, slowing down the rate of infusion, and strictly abiding by the requirement to avoid unnecessary drug combination, in particular for drugs proven to be incompatible. [33] [34] In the clinical setting, as is emphasized in TCM, we should discontinue the medication as soon as we gain effect. It has been proven that 15 to 20 days is an appropriate course of treatment when using QKL to treat stroke. 29 In summary, care should be taken to avoid the occurrence of ADRs when using QKL in the clinical setting. By analyzing the results of the ACI sub-group, the total effective rate was RR=1.18<1.2. This means that QKL used for ACI may not be ideal, although it showed a statistically significant difference. Accordingly, further studies are needed to evaluate QKL comprehensively, for example, whether the economic burden of patients will increase by using QKL, and whether using QKL will alleviate the suffering of patients. The result of the mixed sub-group warrants further research, as the total effective rate was RR=1.34, which was greater than that for the ACI or ACH sub-groups. This could perhaps be related to the quality of the included studies. Thirteen trials were included in the review, but they were not large-scale RCTs, and none of them detailed any random allocation or methods of blinding. Further, all the included studies were published in databases, and there was a lack of negative results, which may have resulted in selection bias. More studies with rigorously designed RCTs are therefore needed. This systematic review showed that the combined use of QKL with WM was effective. The combination may increase the total effective rate, promote the absorption of hematoma, improve the degree of neurological damage and awareness, and decrease the whole blood viscosity coefficient, which can improve efficacy for treating acute stroke. Even though the safety of QKL used for stroke requires further research, it is still one of the first choices for the clinical treatment of stroke.
